{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":53},"studies":[{"active":true,"description":"International cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastine<br />","eudractNumber":"2017-002935-40","id":4034,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"ALK","id":"mt_11"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-14T09:44:08+02:00","shortTitle":"ALCL-VBL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>ALL SCT FORUM Registry 2022</div><div>Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia</div>","eudractNumber":null,"id":9804,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-01T08:39:44+02:00","shortTitle":"ALL SCT FORUM Registry 2022","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />","eudractNumber":null,"id":656,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2012-10-01T09:06:33+02:00","shortTitle":"ALL- REZ BFM","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"ALL-BFM-Register zur Erfassung von Daten von Kindern und Jugendlichen mit akuter lymphoblastischer Leuk&#228;mie in Deutschland","eudractNumber":null,"id":10535,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-01-17T13:12:17+01:00","shortTitle":"ALL-BFM Register","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Register AML-BFM 2017 zur Erfassung akuter myeloischer Leuk&#228;mien bei Kindern und Jugendlichen<br />","eudractNumber":null,"id":3877,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2018-04-03T14:35:25+02:00","shortTitle":"AML-BFM Register 2017","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia. Ant-CD19-ALL.","eudractNumber":"2022-000557-88","id":8720,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05366218","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2023-07-25T10:11:14+02:00","shortTitle":"Anti-CD19-ALL Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"EINE\nPROSPEKTIVE, RANDOMISIERTE, OFFENE PHASE-II-STUDIE ZUR BEURTEILUNG DER\n&#220;BERLEGENHEIT EINER MONOTHERAPIE MIT INOTUZUMAB OZOGAMICIN IM VERGLEICH ZUR\nALLR3 INDUKTIONSTHERAPIE DES P&#196;DIATRISCHEN HOCHRISIKO-ERSTREZIDIVS DER AKUTEN\nLYMPHATISCHEN LEUK&#196;MIE VOM B-VORL&#196;UFER-TYP","eudractNumber":"2022-000186-40","id":8458,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"Others","id":"mt_8"}],"nctNumber":"NCT05748171","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-07-28T09:37:30+02:00","shortTitle":"B1931036","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospektive Erfassung von klinischen Daten, Bildgebungsdaten, Strahlentherapie-Planungsdaten und Biomaterialien zur integrierten Analyse von Therapieansprechen und -resistenz sowie Aufdeckung molekularer Zielstrukturen bei Adoleszenten und jungen Erwachsenen mit ZNS-Tumoren","eudractNumber":null,"id":10994,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT06323408","phase":null,"recruitmentStart":"2024-09-23T15:22:25+02:00","shortTitle":"BZKF-AYA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRalpha/beta and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation","eudractNumber":"2022-001080-27","id":9162,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT05943067","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2024-01-30T10:12:50+01:00","shortTitle":"CD45RADLIHaplo","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"CESS-R-CESS Register","eudractNumber":null,"id":10263,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-11-19T11:10:04+01:00","shortTitle":"CESS Registry","therapeutical":false,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]}]},"initialUrl":"/api/studies?ifs=ped4&lang=de&page=0&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"International cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastine<br />\",\"name\":\"ALCL-VBL\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/4034\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<div>ALL SCT FORUM Registry 2022</div><div>Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia</div>\",\"name\":\"ALL SCT FORUM Registry 2022\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9804\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />\",\"name\":\"ALL- REZ BFM\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/656\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"ALL-BFM-Register zur Erfassung von Daten von Kindern und Jugendlichen mit akuter lymphoblastischer Leuk&#228;mie in Deutschland\",\"name\":\"ALL-BFM Register\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10535\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Register AML-BFM 2017 zur Erfassung akuter myeloischer Leuk&#228;mien bei Kindern und Jugendlichen<br />\",\"name\":\"AML-BFM Register 2017\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/3877\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia. Ant-CD19-ALL.\",\"name\":\"Anti-CD19-ALL Studie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8720\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"EINE\\nPROSPEKTIVE, RANDOMISIERTE, OFFENE PHASE-II-STUDIE ZUR BEURTEILUNG DER\\n&#220;BERLEGENHEIT EINER MONOTHERAPIE MIT INOTUZUMAB OZOGAMICIN IM VERGLEICH ZUR\\nALLR3 INDUKTIONSTHERAPIE DES P&#196;DIATRISCHEN HOCHRISIKO-ERSTREZIDIVS DER AKUTEN\\nLYMPHATISCHEN LEUK&#196;MIE VOM B-VORL&#196;UFER-TYP\",\"name\":\"B1931036\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8458\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prospektive Erfassung von klinischen Daten, Bildgebungsdaten, Strahlentherapie-Planungsdaten und Biomaterialien zur integrierten Analyse von Therapieansprechen und -resistenz sowie Aufdeckung molekularer Zielstrukturen bei Adoleszenten und jungen Erwachsenen mit ZNS-Tumoren\",\"name\":\"BZKF-AYA\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10994\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRalpha/beta and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation\",\"name\":\"CD45RADLIHaplo\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9162\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"CESS-R-CESS Register\",\"name\":\"CESS Registry\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10263\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?ifs=ped4&page=1\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}